Energenesis Biomedical CoTPE:6657 -1.92%64 Quick Ratio is 19.89 as of Dec. 2025, which is 11% below its 10-year median of 22.47. GuruFocus rates TPE:6657 with a GF Score™ of 64/100 and a GF Value™ of NT$51.33 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Energenesis Biomedical Co ranks better than 92.21% on this metric.
Energenesis Biomedical Co has a quick ratio of 19.89. It generally indicates good short-term financial strength.
The historical rank and industry rank for Energenesis Biomedical Co's Quick Ratio or its related term are showing as below:
TPE:6657'
s Quick Ratio Range Over the Past 10 Years
Min: 8.14 Med: 22.47 Max: 35.98
Current: 19.89
During the past 11 years, Energenesis Biomedical Co's highest Quick Ratio was 35.98. The lowest was 8.14. And the median was 22.47.
TPE:6657's Quick Ratio is ranked better than 92.21% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs TPE:6657: 19.89
Energenesis Biomedical Co (TPE:6657) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Energenesis Biomedical Co Quick Ratio Related Terms
Energenesis Biomedical Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6657 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Energenesis Biomedical Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Energenesis Biomedical Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Energenesis Biomedical Co (TPE:6657) has a Quick Ratio of 19.89 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Energenesis Biomedical Co and its competitors. This is 11% below median its historical median of 22.47. Over the past decade, Energenesis Biomedical Co's Quick Ratio has ranged from 8.14 to 35.98. According to the industry distribution chart, Energenesis Biomedical Co ranks #110 out of 1412 companies in the Biotechnology industry, placing it in the top 7.8%.
Is Energenesis Biomedical Co's Quick Ratio too high?
Energenesis Biomedical Co's current Quick Ratio of 19.89 is 11% below median its 10-year median of 22.47. Over the past 10 years, this metric has ranged from a low of 8.14 to a high of 35.98. The Biotechnology industry median Quick Ratio is 3.60. Energenesis Biomedical Co's value of 19.89 is 452.5% above this industry median. Based on the distribution chart, Energenesis Biomedical Co ranks #110 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #110 out of 1412 companies for Quick Ratio. This places Energenesis Biomedical Co in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Energenesis Biomedical Co's value of 19.89 is 452.5% above this benchmark. Historically, Energenesis Biomedical Co's own Quick Ratio has ranged from 8.14 to 35.98 over the past decade. While the company's 10-year median is 22.47 vs. the industry median of 3.60, Energenesis Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Energenesis Biomedical Co's current Quick Ratio of 19.89 is 452.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Energenesis Biomedical Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Energenesis Biomedical Co's current Quick Ratio is 19.89, which is 11% below median its own 10-year median of 22.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.33, compared to a current price of NT$35.70 — trading 30.5% below its estimated fair value. The current Quick Ratio is 19.89, which is 11% below median its 10-year median of 22.47 and 452.5% above the Biotechnology industry median of 3.60. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Quick Ratio is 19.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$35.70 is trading 30.5% below its estimated GF Value™ of NT$51.33.
GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.
Key valuation signals for TPE:6657:
Quick Ratio: 19.89 (11% below median its 10-year median of 22.47)
GF Value™: NT$51.33 vs. price of NT$35.70 (30.5% below fair value)
Industry Position: 452.5% above the Biotechnology median (#110 of 1412)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score
Get the complete analysis for TPE:6657
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
